Avidea Merger with Vaccitech Provides New Opportunities for SNAPvax Platform

Image with the Avidea and Vaccitech logos with an image of Avidea's SNAPvax technology
Published on : Published by : Alex Keown

Privately-held Avidea is developing next-generation T cell immunotherapies for the treatment of cancer and autoimmune diseases. The company’s immunotherapies are driven by its polymer-drug conjugate technology platform, SNAPvax, which is designed to co-deliver multiple antigens and immunomodulators in nanoparticles of precise, programmable size and composition. This is done so in order to enable the development of immunotherapy product candidates with tighter control over immune responses. The SNAPvax platform is designed to induce high magnitude cytotoxic T cells for treating cancer and chronic infections. It can also be configured to induce regulatory T cells for treating autoimmunity and allergies.

Scientific Industries Announces Acquisition of aquila biolabs to Advance Platform for Digitally Simplified Bioprocessing

Published on : Published by : BioBuzz Media

Scientific Industries, Inc. (OTCQB: SCND), a life sciences tool provider, and a developer of optical sensors for non-invasive, real-time monitoring of cell culture systems through its subsidiary Scientific Bioprocessing, Inc. (“SBI”), today announced its acquisition of aquila biolabs GmbH, a privately held German technology developer of smart sensors and state-of-the-art data analytics software for bioprocessing applications under agreed upon terms. The Company believes the acquisition positions the Company to become a leading player in the bioprocessing industry.